Why not just switch on the light?: light and its versatile applications in the field of nanomedicine

Lehner, Roman; Hunziker, Patrick

doi:10.1515/ejnm-2012-0012

Cited by 5 publications

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Near‐Infrared Light‐Triggered Intracellular Delivery of Anticancer Drugs Using Porous Silicon Nanoparticles Conjugated with IR820 Dyes

Xia

Wang

Chen

et al. 2015

Adv Materials Inter

View full text Add to dashboard Cite

A near‐infrared (NIR) light‐triggered system based on porous silicon nanoparticles (PSiNPs) conjugated with IR820 dyes is developed for controlled release of doxorubicin hydrocloride (DOX, anticancer drug) inside cancer cells and chemo‐photothermal combination therapy in vitro. PSiNPs are chosen as nanocarriers to encapsulate IR820 and DOX molecules because of their biocompatibility, biodegradability, and a high loading capacity of effective contents (34.2% ± 6.3%, w/w). Notably, as‐prepared DOX/IR820/PSiNPs nanocomposites also have a high release percentage (98.5%) of DOX molecules triggered by NIR light in acidic environments, compared with that (17.9%) without NIR irradiation under neutral conditions. Furthermore, using localized photostimulation with a femtosecond NIR laser of two‐photo laser scanning confocal microscope, intracellular release of DOX molecules from DOX/IR820/PSiNPs nanocomposites can be dynamically observed in situ. Finally, the combination anticancer treatments of PSiNPs‐based nanocomposites are assessed in vitro, which shows a synergistic effect including chemotherapy and photothermal therapy of cancer cells. Therefore, the therapeutic approach based on PSiNPs‐based nanocarriers integrated with IR820 and DOX molecules has a great potential on NIR light‐stimulated cancer therapy.

show abstract

Near‐Infrared Light‐Triggered Intracellular Delivery of Anticancer Drugs Using Porous Silicon Nanoparticles Conjugated with IR820 Dyes

Xia

Wang

Chen

et al. 2015

Adv Materials Inter

View full text Add to dashboard Cite

show abstract

Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie

et al. 2014

View full text Add to dashboard Cite

Das Interesse der Medizin an der Nanotechnologie hat in kurzer Zeit stark zugenommen. Die Nanotechnologie könnte Lösungen für viele Probleme bieten, die mit herkömmlichen Therapeutika einhergehen, wie etwa eine schlechte Wasserlöslichkeit (zumindest was die meisten Antitumormittel angeht), fehlende Tumorspezifität, nichtspezifische Verteilung, systemische Toxizität und ein geringer therapeutischer Index. In den letzten Jahrzehnten wurden beachtliche Fortschritte bei der Entwicklung und Anwendung von technischen Nanopartikeln gemacht, um Krebs wirksamer zu behandeln. Zum Beispiel gelang der Einbau von Therapeutika in Nanopartikel, die hinsichtlich Größe, Form und Oberflächeneigenschaften optimiert wurden, um deren Löslichkeit zu verbessern, die Halbwertszeit im Blutkreislauf zu verlängern, ihre Bioverteilung zu verbessern und ihre Immunogenität zu verringern. Außerdem wurden auch die pathophysiologischen Bedingungen, wie etwa die bessere Permeabilität und der Retentionseffekt sowie die räumlichen Schwankungen des pH‐Werts genutzt, um einen Transport von Nanopartikeln und ihrer Beladung zu Tumoren zu fördern. Ferner wurden tumordirigierende Liganden (z. B. kleine organische Moleküle, Peptide, Antikörper und Nucleinsäuren) an die Oberfläche von Nanopartikeln addiert, um Krebszellen spezifisch durch selektive Bindung an oberflächenexprimierten Rezeptoren anzusteuern. Es wurde gezeigt, dass viele Arten von therapeutischen und/oder diagnostischen Substanzen (z. B. Kontrastmittel) mithilfe der gleichen Träger transportiert werden können, was Kombinationstherapien und ein Auslesen der Behandlungseffizienz in Echtzeit ermöglicht. Es ist davon auszugehen, dass sich passgenau hergestellte Nanopartikel als nächste Generation von Mitteln zur Krebstherapie und vielen anderen biomedizinischen Anwendungen entwickeln werden.

show abstract

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

et al. 2014

View full text Add to dashboard Cite

In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half-life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real-time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.

show abstract

Why not just switch on the light?: light and its versatile applications in the field of nanomedicine

Cited by 5 publications

References 65 publications

Near‐Infrared Light‐Triggered Intracellular Delivery of Anticancer Drugs Using Porous Silicon Nanoparticles Conjugated with IR820 Dyes

Near‐Infrared Light‐Triggered Intracellular Delivery of Anticancer Drugs Using Porous Silicon Nanoparticles Conjugated with IR820 Dyes

Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Contact Info

Product

Resources

About